FDA , OSI and Genentech Add New Warnings for Tarceva (Erlotinib)

Oncological, Dermatological and Ophthalmological Adverse Events Reported

OSI, Genentech and FDA have notified healthcare professionals of new safety information added to the WARNINGS AND PRECAUTIONS sections of the prescribing information for Tarceva.

Specifically, gastrointestinal perforation (including fatalities), bullous, blistering and exfoliative skin conditions including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, in some cases fatal, and ocular disorders, including corneal perforation or ulceration have been reported during use of Tarceva.

The new safety information comes from routine pharmacovigilance activities of clinical study and postmarketing reports.

Tarceva monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In combination with gemcitabine, Tarceva is also indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Legal Help

If you or a loved one has suffered any of the above adverse events while being treated with this product, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Published on May-8-09